


STN (Registry | Caplus)

10/525, 608

01/24/2007

L1 HAS NO ANSWERS
L1 STR



G1 N, C

G2 H, Me, Et, n-Pr, i-Pr, n-Bu, i-Bu, s-Bu, t-Bu

Structure attributes must be viewed using STN Express query preparation.

=> s 11.ful
FULL SEARCH INITIATED 10:33:41 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 219713 TO ITERATE

100.0% PROCESSED 219713 ITERATIONS
SEARCH TIME: 00.00.03

187 ANSWERS

L2 187 SEA SSS FUL L1

=> fil caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
FULL ESTIMATED COST ENTRY SESSION
172.10 172.31

FILE 'CAPLUS' ENTERED AT 10:33:55 ON 24 JAN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing

of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Jan 2007 VOL 146 ISS 5
FILE LAST UPDATED: 23 Jan 2007 (20070123/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 12

L3 5 L2

=> d ibi abs hitstr 1-5
'IBI' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS ----- GI and AB
ALL ----- BIB, AB, IND, RE
APPS ----- AI, PRAI
BIB ----- AN, plus Bibliographic Data and PI table (default)
CAN ----- List of CA abstract numbers without answer numbers
CBIB ----- AN, plus Compressed Bibliographic Data
CLASS ----- IPC, NCL, ECLA, FTERM
DALL ----- ALL, delimited (end of each field identified)
DMAX ----- MAX, delimited for post-processing
FAM ----- AN, PI and PRAI in table, plus Patent Family data
FBIB ----- AN, BIB, plus Patent FAM
IND ----- Indexing data
IPC ----- International Patent Classifications
MAX ----- ALL, plus Patent FAM, RE
PATTS ----- PI, SO
SAM ----- CC, SX, TI, ST, IT
SCAN ----- CC, SX, TI, ST, IT (random display, no answer numbers;
SCAN must be entered on the same line as the DISPLAY,
e.g., D SCAN or DISPLAY SCAN)
STD ----- BIB, CLASS

IABS ----- ABS, indented with text labels
IALL ----- ALL, indented with text labels
IBIB ----- BIB, indented with text labels
IMAX ----- MAX, indented with text labels
ISTD ----- STD, indented with text labels

OBIB ----- AN, plus Bibliographic Data (original)
OIBIB ----- OBIB, indented with text labels

SBIB ----- BIB, no citations
SIBIB ----- IBIB, no citations

HIT ----- Fields containing hit terms
HITIND ----- IC, ICA, ICI, NCL, CC and index field (ST and IT)
containing hit terms
HITRN ----- HIT RN and its text modification
HITSTR ----- HIT RN, its text modification, its CA index name, and
its structure diagram
HITSEQ ----- HIT RN, its text modification, its CA index name, its
structure diagram, plus NTE and SEQ fields

10/525, 608

01/24/2007

FHITSTR ----- First HIT RN, its text modification, its CA index name, and its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its structure diagram, plus NTE and SEQ fields
KWIC ----- Hit term plus 20 words on either side
OCC ----- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.

ENTER DISPLAY FORMAT (BIB):end

=> d his

(FILE 'HOME' ENTERED AT 10:33:01 ON 24 JAN 2007)

FILE 'REGISTRY' ENTERED AT 10:33:18 ON 24 JAN 2007

L1 STRUCTURE UPLOADED
L2 187 S L1 FUL

FILE 'CAPLUS' ENTERED AT 10:33:55 ON 24 JAN 2007

L3 5 S L2

=> d ibib abs hitstr L3 1-5

L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005-962241 CAPLUS
DOCUMENT NUMBER: 143:266825

TITLE: Preparation of dihydropyridinone derivatives for heart

INVENTOR(S): Gielen-Haertwig, Heike; Albrecht, Barbara; Bauser, Marcus; Keldenich, Joerg; Li, Volkhart; Pernerstorfer, Josef; Schluemer, Karl-Heinz; Tolan, Leila

PATENT ASSIGNEE(S): Bayer Healthcare A.-G., Germany

SOURCE: PCT Int. Appl., 85 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005080372	A1	20050901	WO 2005-EPI192	20050205
W: AD, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BM, GH, GM, KE, LS, MM, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, HR, NE, SN, TD, TG				
CA 2556463	A1	20050901	CA 2005-2556463	20050205
EP 1720847	A1	20061115	EP 2005-701362	20050205
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRIORITY APPLN. INFO.:			EP 2004-3741	A 20040219
			WO 2005-EPI192	W 20050205

OTHER SOURCE(S): MARPAT 143:266825
GI

L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of dihydropyridinone derivs. for heart and lung disease treatment)


RN 863645-30-1 CAPLUS

CN Piperazine, 1-[(5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 863645-32-3 CAPLUS

CN Piperazine, 1-[(5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]-4-cyclohexyl- (9CI) (CA INDEX NAME)



RN 863645-33-4 CAPLUS


CN 4-Piperidinol, 1-[(5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 863645-34-5 CAPLUS

CN Piperazine, 1-[(5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]-4-cycloheptyl- (9CI) (CA INDEX NAME)


L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AB The invention relates to novel dihydropyridinone derivs., processes for their preparation, and their use in medicaments, especially for the treatment of chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction and heart failure development. It was prepared from the corresponding pyridinone-3-carboxylic acid, the synthesis of which is given, and 1-phenylpiperazine. Examples are also given for human neutrophil elastase assays, PMN elastolysis assays, acute lung injury model rats, rats with acute myocardial infarction model in rats.


IT 863645-30-1P 863645-33-3P 863645-33-4P
863645-34-5P 863645-35-6P 863645-36-7P
863645-37-8P 863645-38-9P 863645-40-3P
863645-41-4P 863645-42-5P 863645-43-6P
863645-44-7P 863645-45-8P 863645-46-9P
863645-47-0P 863645-48-1P 863645-49-2P
863645-50-5P 863645-51-6P 863645-52-7P
863645-53-8P 863645-54-9P 863645-55-0P
863645-56-1P 863645-57-2P 863645-58-3P
863645-59-4P 863645-60-5P 863645-61-6P
863645-62-9P 863645-63-0P 863645-64-1P
863645-65-2P 863645-66-3P 863645-67-4P
863645-68-5P 863645-69-6P 863645-70-9P
863645-71-0P 863645-72-1P 863645-73-2P
863645-74-3P 863645-75-4P 863645-76-5P
863645-77-6P 863645-78-7P 863645-79-8P
863645-80-1P 863645-81-2P 863645-82-3P
863645-83-4P 863645-84-5P 863645-85-6P
863645-86-7P 863645-87-8P 863645-88-9P
863645-89-0P 863645-90-1P 863645-91-2P
863645-92-5P 863645-93-6P 863645-94-7P
863645-95-8P 863645-96-9P 863645-97-0P
863645-98-1P 863645-99-2P 863646-00-3P
863646-01-9P 863646-02-0P 863646-03-1P
863646-04-2P 863646-05-3P 863646-06-4P
863646-07-5P

L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 863645-35-6 CAPLUS

CN Piperidine, 1-[(5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 863645-36-7 CAPLUS

CN 3-Pyridinecarboxamide, 5-acetyl-4-(4-cyanophenyl)-N-cyclohexyl-1,2,3,4-tetrahydro-6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 863645-37-8 CAPLUS


CN Thiomorpholine, 4-[(5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued)




RN 863645-38-9 CAPLUS
CN Piperazine, 1-[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl)-4-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 863645-40-3 CAPLUS
CN 1-Piperazineethanamine,
4-[(5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl)carbonyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN


(Continued)



RN 863645-41-4 CAPLUS
CN Piperazine, 1-[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl)-4-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 863645-42-5 CAPLUS
CN Piperazine, 1-[(5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl)carbonyl]-4-(trifluoromethyl)phenyl- (9CI) (CA INDEX NAME)




RN 863645-43-6 CAPLUS
CN Piperazine, 1-[(5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl)carbonyl]-4-[5-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN


(Continued)



RN 863645-44-7 CAPLUS
CN Piperazine, 1-[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl)-4-(4-acetylphenyl)- (9CI) (CA INDEX NAME)




RN 863645-45-8 CAPLUS
CN Piperidine, 1-[(5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl)carbonyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 863645-46-9 CAPLUS
CN Quinoline, 1-[(5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl)carbonyl]-1,2,3,4-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN


(Continued)



RN 863645-47-0 CAPLUS
CN 3-Pyridinecarboxamide, 5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-N,6-dimethyl-N-(4-methylphenyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 863645-48-1 CAPLUS
CN Piperazine, 1-[(5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl)carbonyl]-4-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)




RN 863645-49-2 CAPLUS
CN 3-Pyridinecarboxamide, 5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-N-phenyl-N-(phenylmethyl)-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued)




RN 863645-50-5 CAPLUS

CN 3-Pyridinecarboxamide,
5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-N-(4-methoxyphenyl)methyl-N,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

RN 863645-51-6 CAPLUS

CN Piperazine, 1-[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]pyridinyl]carbonyl-4-(2-furanylcarbonyl)- (9CI) (CA INDEX NAME)




RN 863645-52-7 CAPLUS

CN Piperazine, 1-[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]pyridinyl]carbonyl-4-(4-phenylmethyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 863645-55-0 CAPLUS

CN Piperazine, 1-[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]pyridinyl]carbonyl-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 863645-56-1 CAPLUS

CN 1H-1,4-Diazepine, 1-[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]pyridinyl]carbonylhexahydro-4-methyl- (9CI) (CA INDEX NAME)



RN 863645-57-2 CAPLUS

CN 1H-Azepine, 1-[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]pyridinyl]carbonylhexahydro- (9CI) (CA INDEX NAME)




RN 863645-58-3 CAPLUS


CN 3-Pyridinecarboxamide, 5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-N,6-dimethyl-N-(3-methylphenyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued)




RN 863645-53-8 CAPLUS


CN 1-Piperazinepropanamine,
4-[(5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]pyridinyl]carbonyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

RN 863645-54-9 CAPLUS

CN Piperazine, 1-[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]pyridinyl]carbonyl-4-cyclopentyl- (9CI) (CA INDEX NAME)




L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 863645-59-4 CAPLUS

CN 1,4'-Bipiperidine, 1'-(5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]pyridinyl)- (9CI) (CA INDEX NAME)



RN 863645-60-7 CAPLUS

CN Piperidine, 1-[(5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]pyridinyl)-3-(1-methyl-2-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 863645-61-8 CAPLUS


CN 2-Piperidinecarboxylic acid, 1-[(5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]pyridinyl)-3- (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN


(Continued)



RN 863645-62-9 CAPLUS
CN Piperidine, 1-[(5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl)carbonyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 863645-63-0 CAPLUS
CN 3-Pyridinecarboxamide, 5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-N,6-dimethyl-N-[2-(methylphenylamino)ethyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 863645-64-1 CAPLUS
CN Piperazine, 1-[(5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl)carbonyl]-4-[(4-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN


(Continued)



RN 863645-65-2 CAPLUS
CN Pyrrolidin-1,2-dipyrazine,
2-[(5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl)carbonyl]octahydro- (9CI) (CA INDEX NAME)




RN 863645-66-3 CAPLUS
CN 3-Pyridinecarboxamide, 5-acetyl-4-(4-cyanophenyl)-N-(cyclopropylmethyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-N-propyl-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 863645-67-4 CAPLUS
CN 3-Pyridinecarboxamide,
5-acetyl-N-(2-cyanoethyl)-4-(4-cyanophenyl)-N-ethyl-
1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN


(Continued)



RN 863645-68-5 CAPLUS
CN Piperazine, 1-[(5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl)carbonyl]-4-(2-thienylmethyl)- (9CI) (CA INDEX NAME)




RN 863645-69-6 CAPLUS
CN Piperazine, 1-[(5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl)carbonyl]-4-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 863645-70-9 CAPLUS
CN 3-Pyridinecarboxamide, 5-acetyl-4-(4-cyanophenyl)-N-cyclohexyl-1,2,3,4-tetrahydro-6-methyl-2-oxo-N-[2-(2-pyridinyl)ethyl]-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN


(Continued)



RN 863645-71-0 CAPLUS
CN Piperazine, 1-[(5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl)carbonyl]-4-(tetrahydro-2-furylmethyl)- (9CI) (CA INDEX NAME)




RN 863645-72-1 CAPLUS
CN 3-Pyridinecarboxamide,
5-acetyl-N-(4-cyanomethyl)-4-(4-cyanophenyl)-
1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 863645-73-2 CAPLUS
CN 1-Piperazineacetic acid,
4-[(5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl)carbonyl]-ethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN


(Continued)



RN 863645-74-3 CAPLUS
CN Piperazine, 1-[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]-4-(4-chlorophenyl)-(9CI) (CA INDEX NAME)




RN 863645-75-4 CAPLUS
CN Piperidine, 1-[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)




RN 863645-76-5 CAPLUS
CN Piperazine, 1-[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]-4-(2-(4-morpholinyl)ethyl)-(9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN


(Continued)



RN 863645-77-6 CAPLUS
CN N-Alanine, N-[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]-N-cyclopropyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 863645-78-7 CAPLUS
CN Carbamic acid, [1-[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]-4-piperidinyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 863645-79-8 CAPLUS
CN 3-Pyridinecarboxamide, 5-acetyl-4-(4-cyanophenyl)-N-cyclohexyl-N-(3-trifluoromethyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-(9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued)




RN 863645-80-1 CAPLUS
CN Azetidine, 1-[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]-3-(4-(trifluoromethyl)phenoxy)-(9CI) (CA INDEX NAME)




RN 863645-81-2 CAPLUS
CN Azetidine, 1-[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]-3-phenoxy-(9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN


(Continued)



RN 863645-82-3 CAPLUS
CN 3-Pyridinecarboxamide, 5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-N,6-dimethyl-N-(3-nitrophenyl)methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-(9CI) (CA INDEX NAME)




RN 863645-83-4 CAPLUS
CN Quinoline, 1-[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]-6-fluoro-1,2,3,4-tetrahydro-2-methyl-(9CI) (CA INDEX NAME)




RN 863645-84-5 CAPLUS
CN 4-Piperidinone, 1-[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-


L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 2-oxo-1-(3-(trifluoromethyl)phenyl)-3-pyridinyl]carbonyl]-,
 4-(O-methoxyimine) (9CI) (CA INDEX NAME)



RN 863645-85-6 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[(5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-(3-(trifluoromethyl)phenyl)-3-pyridinyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 863645-86-7 CAPLUS
 CN 3-Pyridinecarboxamide, 5-acetyl-4-(4-cyanophenyl)-N-[(4-(diethylamino)phenyl)methyl]-1,2,3,4-tetrahydro-N,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 863645-87-8 CAPLUS
 CN 3-Pyridinecarboxamide, 5-acetyl-4-(4-cyanophenyl)-N-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI)


L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 863645-91-4 CAPLUS
 CN 3-Pyridinecarboxamide, 5-acetyl-N-(2-(2-chlorophenyl)ethyl)-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 863645-92-5 CAPLUS
 CN 3-Pyridinecarboxamide, 5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-N-(3-(2-methoxyethoxy)propyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 863645-93-6 CAPLUS
 CN 3-Pyridinecarboxamide, 5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-N-(2-phenoxyethyl)-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (CA INDEX NAME) (Continued)



RN 863645-88-9 CAPLUS
 CN Piperazine, 1-[(5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]-4-(2-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 863645-89-0 CAPLUS
 CN 3-Pyridinecarboxamide, 5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-N-(2-(4-hydroxy-3-methoxyphenyl)ethyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 863645-90-3 CAPLUS
 CN 3-Pyridinecarboxamide, 5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-N-(2-(3-(trifluoromethyl)phenyl)ethyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 863645-94-7 CAPLUS
 CN 3-Pyridinecarboxamide, 5-acetyl-4-(4-cyanophenyl)-N-[(4,6-dimethyl-2-pyrimidinyl)methyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 863645-95-8 CAPLUS
 CN 3-Pyridinecarboxamide, 5-acetyl-N-[(2-chlorophenyl)methyl]-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 863645-96-9 CAPLUS
 CN 3-Pyridinecarboxamide, 5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-N-[(4-(trifluoromethoxy)phenyl)methyl]-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 863645-97-0 CAPLUS
 CN 3-Pyridinecarboxamide, 5-acetyl-N-[(3-chlorophenyl)methyl]-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued)




RN 863645-98-1 CAPLUS

CN 3-Pyridinecarboxamide, 5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 863645-99-2 CAPLUS

CN 3-Pyridinecarboxamide, 5-acetyl-4-(4-cyanophenyl)-N-(2,4-dimethylphenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 863646-00-8 CAPLUS

CN 3-Pyridinecarboxamide, 5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-N-(4-methyl-1-piperazinyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued)




RN 863646-04-2 CAPLUS

CN Benzoic acid, 4-[(5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl)carbonyl]amino)methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 863646-05-3 CAPLUS

CN 3-Pyridinecarboxamide, 5-acetyl-4-(4-cyanophenyl)-N-(3,5-dimethylphenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 863646-06-4 CAPLUS

CN 3-Pyridinecarboxamide, 5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-N-[2-(3-methoxyphenyl)ethyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued)




RN 863646-07-5 CAPLUS

CN 3-Pyridinecarboxamide, 5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-N-[3-(4-(2-methoxyphenyl)-1-piperazinyl)propyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 863646-02-0 CAPLUS

CN 3-Pyridinecarboxamide, 5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-N-[2-(4-hydroxy-3,5-dimethoxyphenyl)ethyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 863646-03-1 CAPLUS

CN 3-Pyridinecarboxamide, 5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-N-[2-(methylphenylamino)ethyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued)




L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued)



RN 863646-07-5 CAPLUS

CN 3-Pyridinecarboxamide, 5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-N-[3-(4-(2-methoxyphenyl)-1-piperazinyl)propyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:203810 CAPLUS
 DOCUMENT NUMBER: 140:235612

TITLE: Preparation of dihydropyridinones as human neutrophil elastase (HNE) inhibitors
 INVENTOR(S): Giesen, Heike; Li, Volkart Min-Jian; Rosentreter, Ulrich; Schlemmer, Karl-Heinz; Allerheiligen, Sven; Telan, Leila; Baerfacker, Lars; Keldenich, Joerg; Fitzgerald, Mary F.; Nash, Kevin; Albrecht, Barbara; Meurer, Dirk

PATENT ASSIGNEE(S): Bayer Healthcare A.-G., Germany
 SOURCE: PCT Int. Appl... 166 pp.

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004020410	A2	20040311	WO 2003-EP9108	20030818
WO 2004020410	A3	20040422		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MW, MY, MZ, NI, NO, N2, OM, PG, PH, PL, PT, RO, RU, SK, SD, SE, SG, SK, SL, SY, TJ, TM, TH, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TR, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BY, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2496815	A1	20040311	CA 2003-2496815	20030818
AU 2003293356	A1	20040319	AU 2003-293356	20030818
EP 1554246	A2	20050720	EP 2003-340904	20030818
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, MC, PT, SI, LT, LV, FI, RO, MK, CY, MT, TR, BG, CZ, EE, HU, SK				
JP 2006503820	T	20060202	JP 2004-532090	20030818
US 2006100207	A1	20060511	US 2005-525608	20051013
GB 2002-19894			GB 2002-19894	A 20020827
GB 2002-21143	A		GB 2002-21143	A 20020912
WO 2003-EP9108			WO 2003-EP9108	W 20030818

PRIORITY APPLN. INFO.:

OTHER SOURCE(S): MARPAT 140:235612
 GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I (wherein A = hetero/aryl; R1, R2, R3 = independently H, halo, NO2, CN, CF3, (un)substituted alkyl, OH and derivs., R4 = alkenoxycarbonyl, hydroxycarbonyl, CN, (un)substituted alkylcarbonyl,

L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 (Process); USES (Uses)
 (human neutrophil elastase inhibitor; prepn. of dihydropyridinones as human neutrophil elastase inhibitors)


RN 668998-87-6 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 668998-93-4 CAPLUS

CN 3-Pyridinecarboxamide, 5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



IT 668999-86-8P 669000-45-7P, (+)-Diethyl

4-(4-cyanophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-3-pyridinedicarboxylate
 RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(human neutrophil elastase inhibitor; preparation of dihydropyridinones as human neutrophil elastase inhibitors)

RN 668999-86-8 CAPLUS

CN 3-Pyridinecarboxamide, 5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, (3R,4S)-rel-(-) (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.

L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 alkoxy carbonyl, alkyl/cycloalkyl/N-(heterocyclic)/mono/di/amino carbonyl; R5 = alkyl; R6 = H, alkyl/cycloalkyl/alkyl/amino carbonyl, cycloalkyl carbonyl, aryl carbonyl, hydroxyl carbonyl, alkenoxyl carbonyl, aryl oxycarbonyl, (un)substituted mono/di/aryl/amino carbonyl, 4-carboxylmorpholinyl, etc.; R7 = H, halo, NO2, CN, CF3, (un)substituted alkyl, alkoxy; , Y1, Y2, Y3, Y4, Y5 = independently CH or N; and their salts, hydrates, and/or solvates, and their tautomeric forms;

were prep'd. as human neutrophil elastase (HNE) inhibitors. For example, II was prep'd. by cyclocondensation of III (prep'n. given) with 4-formylbenzonitrile and 2-cyanoacetamide in the presence of EtOH/piperazine, followed by reaction with water in acetic acid. In an in vitro assay, I inhibited HNE with IC50 values within the range of 5 nM -

5 μM. Thus, I are useful for treatment of chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction and heart failure development.

IT 668998-95-6 CAPLUS

RL: BYP (Byproduct); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(human neutrophil elastase inhibitor; preparation of dihydropyridinones as

human neutrophil elastase inhibitors)


RN 669998-95-6 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-

methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 5-((1R)-1-carboxyethyl)-


3-ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 668998-87-6P, Diethyl 4-(4-cyanophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-3-pyridinedicarboxylate
 668998-93-4P, 5-Cyano-4-(4-cyanophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-3-pyridinecarboxamide
 RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC


L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 669000-45-7 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, diethyl ester, (3R,4R)-rel-(-) (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.



IT 668999-32-4P, Allyl 4-(4-cyanophenyl)-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxylate
 668999-33-5P, 4-(4-Cyanophenyl)-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxylic acid
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(human neutrophil elastase inhibitor; preparation of dihydropyridinones as human neutrophil elastase inhibitors)

RN 669999-32-4 CAPLUS


CN 3-Pyridinecarboxylic acid,

4-(4-cyanophenyl)-1,4,5,6-tetrahydro-2-methyl-6-


oxo-1-[3-(trifluoromethyl)phenyl]-, 2-propenyl ester (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.

L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 668999-33-5 CAPLUS
 CN 3-Pyridinecarboxylic acid,
 4-(4-cyanophenyl)-1,4,5,6-tetrahydro-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




IT 668998-88-7P, Ethyl 5-(aminocarbonyl)-4-(4-cyanophenyl)-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxylate
 668998-90-10, Ethyl 5-acetyl-4-(4-cyanophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-3-pyridinecarboxylate
 668998-91-2P, Ethyl 4-(4-cyanophenyl)-5-[(dimethylamino)carbonyl]-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxylate 668998-92-3P, Ethyl 5-cyano-4-(4-cyanophenyl)-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxylate 668998-94-5P
 668998-96-7P, Ethyl 5-cyano-4-(4-cyanophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-3-pyridinecarboxylate 668998-97-8P, Ethyl 5-cyano-4-(4-methoxycarbonyl)phenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-3-pyridinecarboxylate 668998-98-9P, 5-Cyano-4-(4-cyanophenyl)-N,N-dimethyl-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-3-pyridinecarboxamide 668998-99-0P, N-Acetyl-4-(4-cyanophenyl)-N,N-dimethyl-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-3-pyridinecarboxamide 668998-99-0P, Ethyl 4-(4-cyanophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-3-pyridinecarboxylate 668998-99-0P, Ethyl 4-(4-cyanophenyl)-5-[(cyclopropylamino)carbonyl]-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxylate 668998-99-0P, Ethyl

L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 tetrahydropyridine-3-carboxylic acid N-(2-hydroxyethyl)amide

668999-57-3P, 4-(4-cyanophenyl)-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydropyridine-3-carboxylic acid cyclopropylamine 668999-58-4P 668999-59-5P
 668999-60-8P 668999-61-9P 668999-62-0P
 668999-63-1P 668999-64-2P 668999-65-3P
 668999-66-4P 668999-67-5P 668999-68-6P
 668999-69-7P 668999-70-8P 668999-71-1P
 668999-72-2P 668999-73-3P 668999-74-4P
 668999-75-5P 668999-76-6P 668999-77-7P,
 4-(4-cyanophenyl)-5-cyclopropylcarbonyl-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydropyridine-3-carboxylic acid ethyl ester 668999-78-8P 668999-79-9P
 668999-80-2P 668999-81-3P 668999-82-4P
 668999-83-5P 668999-84-6P 668999-85-7P
 668999-87-9P, N-[2-(Benzoyloxy)ethyl]-5-cyano-4-(4-cyanophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-3-pyridinecarboxamide 668999-88-0P, 2-[(5-Cyano-4-(4-cyanophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-3-pyridyl)carbonyl]aminoethyl methanesulfonate RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (human neutrophil elastase inhibitor; prepn. of dihydropyridinones as human neutrophil elastase inhibitors)

RN 668998-88-7 CAPLUS
 CN 3-Pyridinecarboxylic acid, 5-(aminocarbonyl)-4-(4-cyanophenyl)-1,4,5,6-tetrahydro-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 668998-90-1 CAPLUS
 CN 3-Pyridinecarboxylic acid,
 5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 4-(4-cyanophenyl)-5-[(isopropylamino)carbonyl]-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydropyridinecarboxylate 668999-04-0P 668999-05-1P 668999-06-2P,
 5-Cyano-4-(4-cyanophenyl)-N-(2-methoxyethyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyridinecarboxamide 668999-07-3P 668999-08-4P 668999-09-5P
 668999-10-8P 668999-11-9P 668999-12-0P
 668999-13-1P 668999-14-2P 668999-15-3P
 668999-16-4P 668999-17-5P 668999-18-6P
 668999-19-7P, Diethyl 4-(4-cyanophenyl)-6-methyl-2-oxo-5'-((trifluoromethyl)-3,4-dihydro-2H-1,3'-bipyridine-3,5-dicarboxylate 668999-20-0P, Ethyl 4-(4-cyanophenyl)-2-methyl-6-oxo-1-[3-


pyrrolydinyl]carbonyl]-1-[3-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydropyridinecarboxylate 668999-21-1P, Ethyl 4-(4-cyanophenyl)-5-((12-methoxyethyl)(methylamino)carbonyl)-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydropyridinecarboxylate 668999-22-2P, Ethyl 4-(4-cyanophenyl)-5-[(diethylamino)carbonyl]-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydropyridinecarboxylate 668999-23-3P, Ethyl 4-(4-cyanophenyl)-2-methyl-5-[(4-methyl-1-piperazinyl)carbonyl]-6-oxo-1-[3-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydropyridinecarboxylate 668999-24-4P, Ethyl 4-(4-cyanophenyl)-2-methyl-6-oxo-5-[(1,3-thiazolidin-3-yl)carbonyl]-1-[3-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydropyridinecarboxylate 668999-25-5P, Ethyl 5-6-dicyanomethyl-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydropyridine-3,4-bipyridine-3'-carboxylate 668999-26-6P, 2-Methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-1',4',5',6'-tetrahydropyridine-3,4'-bipyridine-3',6-dicarboxylic acid 668999-27-7P, Ethyl 4-(4-cyanophenyl)-2-methyl-5-[(4-methyl-1-piperazinyl)carbonyl]-6-oxo-1-[3-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydropyridinecarboxylate 668999-28-8P, Diethyl 4-(4-chlorophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyridine-3,5-pyridinedicarboxylate 668999-29-9P, 4-(4-cyanophenyl)-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydropyridinecarboxylate 668999-30-0P, 4-(5-Acetyl-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyridyl)benzonitrile 668999-31-3P, 4-(5-Acetyl-6-methyl-3-[(4-morpholinyl)carbonyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyridylbenzonitrile 668999-34-6P, 2-Hydrazinyl-4-(4-cyanophenyl)-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydropyridine-3-pyridinecarboxylate 668999-35-7P, 2-(Dimethylamino)ethyl 4-(4-cyanophenyl)-2-methyl-6-

oxo-1-[3-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydropyridine-3-pyridinecarboxylate 668999-36-8P 668999-37-9P, 2-(Acetylamino)ethyl 4-(4-cyanophenyl)-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydropyridinecarboxylate 668999-38-0P 668999-39-1P 668999-41-5P 668999-44-8P 668999-45-9P 668999-46-0P 668999-47-1P 668999-48-2P 668999-49-3P 668999-50-6P 668999-51-7P 668999-52-8P 668999-53-9P 668999-54-0P 668999-55-1P, [(5-Cyano-4-(4-cyanophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyridin-3-yl)carbonyl]aminoacetic acid 668999-56-2P, 5-Cyano-4-(4-cyanophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-


L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 668998-91-2 CAPLUS
 CN 3-Pyridinecarboxylic acid, 4-(4-cyanophenyl)-5-[(dimethylamino)carbonyl]-1,4,5,6-tetrahydro-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 668998-92-3 CAPLUS
 CN 3-Pyridinecarboxylic acid,
 5-cyano-4-(4-cyanophenyl)-1,4,5,6-tetrahydro-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 668998-94-5 CAPLUS
 CN 3,5-Pyridinedicarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-2-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 3-ethyl 5-[(IR)-2-methoxy-1-methyl-2-oxoethyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 668998-96-7 CAPLUS
CN 3-Pyridinecarboxylic acid, 5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 668998-97-8 CAPLUS
CN 3-Pyridinecarboxylic acid, 5-cyano-1,2,3,4-tetrahydro-4-(4-(methoxycarbonyl)phenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 668998-98-9 CAPLUS
CN 3-Pyridinecarboxamide, 5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-N,N,6-trimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 668999-03-9 CAPLUS
CN 3-Pyridinecarboxylic acid, 4-(4-cyanophenyl)-1,4,5,6-tetrahydro-2-methyl-5-[(1-methylethyl)amino]carbonyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 668999-04-0 CAPLUS
CN β -Alanine, N-[(5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]3-pyridinyl)carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 668999-05-1 CAPLUS
CN β -Alanine, N-[(5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]3-pyridinyl)carbonyl]- (CA INDEX NAME)


L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 668998-99-0 CAPLUS
CN 3-Pyridinecarboxamide, 5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-N,N,6-trimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 668999-00-6 CAPLUS
CN 3-Pyridinecarboxylic acid, 4-(4-cyanophenyl)-1,4,5,6-tetrahydro-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 668999-02-8 CAPLUS
CN 3-Pyridinecarboxylic acid, 4-(4-cyanophenyl)-5-[(cyclopropylamino)carbonyl]-1,4,5,6-tetrahydro-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)


L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 668999-03-9 CAPLUS
CN 3-Pyridinecarboxylic acid, 4-(4-cyanophenyl)-1,4,5,6-tetrahydro-2-methyl-5-[(1-methylethyl)amino]carbonyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 668999-04-0 CAPLUS
CN β -Alanine, N-[(5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]3-pyridinyl)carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 668999-05-1 CAPLUS
CN β -Alanine, N-[(5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]3-pyridinyl)carbonyl]- (CA INDEX NAME)

L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 668999-06-2 CAPLUS
CN 3-Pyridinecarboxamide, 5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-N-(2-methoxyethyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 668999-07-3 CAPLUS
CN D-Alanine, N-[(3S,4R)-5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]3-pyridinyl]carbonyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 668999-08-4 CAPLUS
CN D-Alanine, N-[(3R,4R)-5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]3-pyridinyl]carbonyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued)




RN 668999-09-5 CAPLUS
 CN D-Alanine, N-[(3S,4S)-5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 668999-10-8 CAPLUS
 CN 3-Pyridinecarboxamide, 5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-N-[(1R)-1-phenylethyl]-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 668999-11-9 CAPLUS


L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN 3-Pyridinecarboxamide, 5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-N-[(1R)-1-phenylethyl]-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668999-12-0 CAPLUS
 CN D-Alanine, N-[(3S,4S)-5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl-, ethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 668999-13-1 CAPLUS
 CN D-Alanine, N-[(3S,4R)-5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl-, ethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN


(Continued)



RN 668999-14-2 CAPLUS
 CN 3-Pyridinecarboxamide, 4-(4-bromophenyl)-5-cyano-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 668999-15-3 CAPLUS
 CN 3-Pyridinecarboxamide, 5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-N,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 668999-16-4 CAPLUS
 CN 3-Pyridinecarboxamide, 5-cyano-4-(4-cyano-2-methylphenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 668999-17-5 CAPLUS
 CN 3-Pyridinecarboxamide, N-(4-bromophenyl)-5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 668999-18-6 CAPLUS
 CN 3-Pyridinecarboxamide, 5-cyano-4-(4-cyanophenyl)-N-ethyl-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 668999-19-7 CAPLUS
 CN [1(2H),3'-Bipyridine]-3,5-dicarboxylic acid, 4-(4-cyanophenyl)-3-dihydro-6-methyl-2-oxo-5'-(trifluoromethyl)-, diethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN


(Continued)



RN 668999-20-0 CAPLUS
CN 3-Pyridinecarboxylic acid, 4-(4-cyanophenyl)-1,4,5,6-tetrahydro-2-methyl-6-oxo-5-[1-pyrrolidinylcarbonyl]-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 668999-21-1 CAPLUS
CN 3-Pyridinecarboxylic acid, 4-(4-cyanophenyl)-1,4,5,6-tetrahydro-5-[(2-methoxyethyl)methylamino]carbonyl]-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 668999-22-2 CAPLUS

 $\gamma = N$


546/257

514/334

546/279.1


514/343

L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 3-Pyridinecarboxylic acid, 4-(4-cyanophenyl)-5-[(diethylamino)carbonyl]-1,4,5,6-tetrahydro-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)

General
546/299 (298)

514/350

RN 668999-23-3 CAPLUS
CN 3-Pyridinecarboxylic acid, 4-(4-cyanophenyl)-1,4,5,6-tetrahydro-2-methyl-5-(4-morpholinylcarbonyl)-6-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




544/131

514/235.5

RN 668999-24-4 CAPLUS
CN 3-Pyridinecarboxylic acid, 4-(4-cyanophenyl)-1,4,5,6-tetrahydro-2-methyl-6-oxo-5-(3-chazolidinylcarbonyl)-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)


L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



546/269.7


514/342

RN 668999-25-5 CAPLUS
CN [3,4'-Bipyridine]-3'-carboxylic acid, 5',6-dicyano-1',2',3',4'-tetrahydro-6'-methyl-2'-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




A = Het ✓

RN 668999-26-6 CAPLUS
CN [3,4'-Bipyridine]-3',6-dicarbonitrile, 1',4',5',6'-tetrahydro-2'-methyl-6'-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 668999-27-7 CAPLUS
CN 3-Pyridinecarboxylic acid, 4-(4-cyanophenyl)-1,4,5,6-tetrahydro-2-methyl-5-[(4-methyl-1-piperazinyl)carbonyl]-6-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)


L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




544/365

514/253.12

RN 668999-28-8 CAPLUS
CN 3,5-Pyridinedicarboxylic acid, 4-(4-chlorophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 668999-29-9 CAPLUS
CN 3-Pyridinecarbonitrile, 4-(4-cyanophenyl)-1,4,5,6-tetrahydro-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




514/351


RN 668999-30-2 CAPLUS
CN Benzonitrile, 4-[5-acetyl-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued)




RN 668999-31-3 CAPLUS
CN Morpholine, 4-[(5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl- (9CI) (CA INDEX NAME)




✓ 544

RN 668999-34-6 CAPLUS
CN 3-Pyridinecarboxylic acid,
4-(4-cyanophenyl)-1,4,5,6-tetrahydro-2-methyl-6-
oxo-1-[3-(trifluoromethyl)phenyl]-, 2-hydroxyethyl ester (9CI) (CA INDEX NAME)




RN 668999-35-7 CAPLUS
CN 3-Pyridinecarboxylic acid,
4-(4-cyanophenyl)-1,4,5,6-tetrahydro-2-methyl-6-
oxo-1-[3-(trifluoromethyl)phenyl]-, 2-(dimethylamino)ethyl ester (9CI)


L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 668999-38-0 CAPLUS
CN 3-Pyridinecarboxamide, 5-cyano-4-(4-cyanophenyl)-N-[2-[(1,1-
dimethylethyl)dimethylsilyl]oxy]ethyl-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-
(3-(trifluoromethyl)phenyl)- (9CI) (CA INDEX NAME)




RN 668999-39-1 CAPLUS
CN 3-Pyridinecarboxamide, 5-cyano-N-ethyl-1,2,3,4-tetrahydro-6-methyl-4-(4-
nitrophenyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 668999-41-5 CAPLUS
CN 3-Pyridinecarboxamide, 5-cyano-1,2,3,4-tetrahydro-6-methyl-4-(4-
nitrophenyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (CA INDEX NAME)




RN 668999-36-8 CAPLUS
CN 3-Pyridinecarboxylic acid,
4-(4-cyanophenyl)-1,4,5,6-tetrahydro-2-methyl-6-
oxo-1-[3-(trifluoromethyl)phenyl]-, 2-(1-pyrrolidinyl)ethyl ester (9CI) (CA INDEX NAME)




RN 668999-37-9 CAPLUS
CN 3-Pyridinecarboxylic acid,
4-(4-cyanophenyl)-1,4,5,6-tetrahydro-2-methyl-6-
oxo-1-[3-(trifluoromethyl)phenyl]-, 2-(acetylamino)ethyl ester (9CI) (CA INDEX NAME)


L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 668999-44-8 CAPLUS
CN 3-Pyridinecarboxamide, 5-cyano-4-(4-cyanophenyl)-N-ethyl-1,2,3,4-
tetrahydro-6-methyl-1-(3-methylphenyl)-2-oxo- (9CI) (CA INDEX NAME)




RN 668999-45-9 CAPLUS
CN 3-Pyridinecarboxamide, 5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-
methyl-1-(3-methylphenyl)-2-oxo- (9CI) (CA INDEX NAME)




RN 668999-46-0 CAPLUS
CN 3-Pyridinecarboxylic acid, 1-(3-chlorophenyl)-5-cyano-4-(4-cyanophenyl)-N-
ethyl-1,2,3,4-tetrahydro-6-methyl-2-oxo- (9CI) (CA INDEX NAME)


L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 668999-60-8 CAPLUS
CN 3-Pyridinecarboxamide, 4-(4-cyanophenyl)-N-[2-(2-fluorophenyl)ethyl]-1,4,5,6-tetrahydro-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 668999-61-9 CAPLUS
CN 3-Pyridinecarboxamide, 4-(4-cyanophenyl)-N-[2-(2-fluorophenyl)methyl]-1,4,5,6-tetrahydro-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 668999-62-0 CAPLUS

L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 3-Pyridinecarboxamide, 4-(4-cyanophenyl)-N-[2-(dimethylamino)ethyl]-1,4,5,6-tetrahydro-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


RN 668999-63-1 CAPLUS
CN 3-Pyridinecarboxamide, 4-(4-cyanophenyl)-1,4,5,6-tetrahydro-N-(2-methoxyethyl)-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 668999-64-2 CAPLUS
CN 3-Pyridinecarboxamide, 4-(4-cyanophenyl)-1,4,5,6-tetrahydro-2-methyl-N-(2-methylpropyl)-6-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 668999-65-3 CAPLUS
CN 3-Pyridinecarboxamide, 4-(4-cyanophenyl)-N-ethyl-1,4,5,6-tetrahydro-2-


L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Absolute stereochemistry.

RN 668999-66-4 CAPLUS
CN 3-Pyridinecarboxamide, 4-(4-cyanophenyl)-1,4,5,6-tetrahydro-N,2-dimethyl-6-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 668999-67-5 CAPLUS
CN 3-Pyridinecarboxamide, 5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-N-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668999-68-6 CAPLUS
CN 3-Pyridinecarboxamide, 5-cyano-4-(4-cyanophenyl)-N-[(1S)-2-(dimethylamino)-1-methyl-2-oxoethyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

544 ✓

L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Absolute stereochemistry.


RN 668999-69-7 CAPLUS
CN 3-Pyridinecarboxamide, 5-cyano-4-(4-cyanophenyl)-N-[(1S)-2-(cyclopropylamino)-1-methyl-2-oxoethyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668999-70-0 CAPLUS
CN 3-Pyridinecarboxamide, 5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-N-[(1S)-2-(2-methoxyethyl)amino]-1-methyl-2-oxo-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 668999-71-1 CAPLUS
CN 3-Pyridinecarboxamide, 5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-N-[(1S)-1-methyl-2-(methylamino)-2-oxoethyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
(tri trifluoromethylphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 668999-72-2 CAPLUS
CN 3-Pyridinecarboxamide, 5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-N-[3-(4-morpholinyl)-3-oxopropyl]-2-oxo-1-[3-(trifluoromethylphenyl)- (9CI) (CA INDEX NAME)




RN 668999-73-3 CAPLUS
CN 3-Pyridinecarboxamide, 5-cyano-4-(4-cyanophenyl)-N-[3-(dimethylamino)-3-oxopropyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethylphenyl)- (9CI) (CA INDEX NAME)




RN 668999-74-4 CAPLUS
CN 3-Pyridinecarboxamide, 5-cyano-4-(4-cyanophenyl)-N-[3-(cyclopiropylamino)-3-oxopropyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethylphenyl)-


L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 668999-78-8 CAPLUS
CN 3,5-Pyridinedicarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethylphenyl)-, 5-ethyl 3-(2-methoxyethyl)ester (9CI) (CA INDEX NAME)



RN 668999-79-9 CAPLUS
CN 3,5-Pyridinedicarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethylphenyl)-, 5-ethyl 3-phenyl ester (9CI) (CA INDEX NAME)




RN 668999-80-2 CAPLUS
CN 3,5-Pyridinedicarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethylphenyl)-, 5-ethyl 3-(2-propenyl) ester (9CI) (CA INDEX NAME)


(Continued)

L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
(9CI) (CA INDEX NAME)


(Continued)



RN 668999-75-5 CAPLUS
CN 3-Pyridinecarboxamide, 5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-N-[3-(2-methoxyethyl)amino]-3-oxopropyl]-6-methyl-2-oxo-1-[3-(trifluoromethylphenyl)- (9CI) (CA INDEX NAME)




RN 668999-76-6 CAPLUS
CN 3-Pyridinecarboxamide, 5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-N-[3-(methylamino)-3-oxopropyl]-2-oxo-1-[3-(trifluoromethylphenyl)- (9CI) (CA INDEX NAME)




RN 668999-77-7 CAPLUS
CN 3-Pyridinecarboxylic acid, 4-(4-cyanophenyl)-5-(cyclopropylcarbonyl)-1,4,5,6-tetrahydro-2-methyl-6-oxo-1-[3-(trifluoromethylphenyl)-, ethyl ester (9CI) (CA INDEX NAME)


L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 668999-81-3 CAPLUS
CN 3-Pyridinecarboxylic acid, 5-[(4-acetyl-1-piperazinyl)carbonyl]-4-(4-cyanophenyl)-1,4,5,6-tetrahydro-2-methyl-6-oxo-1-[3-(trifluoromethylphenyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 668999-82-4 CAPLUS
CN 3-Pyridinecarboxylic acid, 5-[(bis(1-methylethyl)amino)carbonyl]-4-(4-cyanophenyl)-1,4,5,6-tetrahydro-2-methyl-6-oxo-1-[3-(trifluoromethylphenyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 668999-83-5 CAPLUS
CN 3-Pyridinecarboxylic acid, 4-(4-cyanophenyl)-1,4,5,6-tetrahydro-2-methyl-5-[(methylphenylamino)carbonyl]-6-oxo-1-[3-(trifluoromethylphenyl)-, ethyl ester (9CI) (CA INDEX NAME)


L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued)




RN 668999-84-6 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-benzoyl-4-(4-cyanophenyl)-1,4,5,6-tetrahydro-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 668999-85-7 CAPLUS

CN 3-Pyridinecarboxylic acid, 4-(4-cyanophenyl)-1,4,5,6-tetrahydro-2-methyl-6-oxo-5-(1-oxobutyl)-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 668999-87-9 CAPLUS

CN 3-Pyridinecarboxamide, 5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-N-[2-(phenylmethoxy)ethyl]-1-[3-(trifluoromethyl)phenyl]-

L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (prepn. of dihydropyridinones as human neutrophil elastase inhibitors)


RN 669000-46-8 CAPLUS

CN [3,4'-Bipyridine]-3'-carboxamide, 5',6-dicyano-N-ethyl-1',2',3',4'-tetrahydro-6'-methyl-2'-oxo-1'-(3-(trifluoromethyl)phenyl)- (9CI) (CA INDEX NAME)

*A = het ✓*


L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (9CI) (CA INDEX NAME)

(Continued)



RN 668999-88-0 CAPLUS

CN 3-Pyridinecarboxamide, 5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-N-[2-(methylsulfonyloxy)ethyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




IT 669000-16-2P, Ethyl 4-(4-chlorophenyl)-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxylate
 RL: RCT (Reactant); SEN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of dihydropyridinones as human neutrophil elastase inhibitors)

RN 669000-16-2 CAPLUS

CN 3-Pyridinecarboxylic acid,

4-(4-chlorophenyl)-1,4,5,6-tetrahydro-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




IT 669000-46-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

L3 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1991:535744 CAPLUS
 DOCUMENT NUMBER: 115:135744
 TITLE: Preparation of 3-alkyl β -lactams via the ketene imine cycloaddition reaction using α -(phenylthio)alkenyl halides as starting materials: application to the synthesis of (*i*)-carbapenem building blocks and related compounds

AUTHOR(S): Palomo, Claudio; Cossío, Fernando P.; Odiozola, Jose M.; Olarriba, Mikel; Ontoria, Jesus M.
 CORPORATE SOURCE: Fac. Quím., Univ. País Vasco, San Sebastián, 20080, Spain
 SOURCE: Journal of Organic Chemistry (1991), 56(14), 4418-28
 DOCUMENT TYPE: CODEN: JOCEAH; ISSN: 0022-3263
 LANGUAGE: Journal
 OTHER SOURCE(S): English
 GI: CASREACT 115:135744



AB Preparation of appropriately substituted 3-alkyl β -lactams via the ketene

(or equivalent)-imine cycloaddn. reaction is described. The dehydrochlorination of 4-RC6H4SCHR1COCl (R = H, Me, Cl; R1 = H, Me, Et, CHMe2) with Et3N in the presence of R2NC(R3) (R2 = Bz, MeOC2, PhC6H4CO, PhCH2C6H4, PhCH(C6H4)2, PhCH(C6H4)2) or 4-MeOC6H4N; CHCR4:CHPh (R4 = H, Me, Ph) produced a high-yield of α -phenylthio β -lactams, which upon desulfurization furnished 3-alkyl β -lactams I and II in a highly stereoselective fashion. In contrast, reaction between RCH(Cl)COCl and cinnamylideneamines in the presence of Et3N furnished [4 + 2] cycloadducts as main products.

Preparation of highly functionalized α -alkylidene β -lactams through thermal decomposition of the corresponding β -lactam sulfoxides or by cycloaddn.

of α,β -unsatd. acid chlorides to imino esters in the presence of triethylamine is also described.

IT 135616-42-1P 135616-43-2P
 RL: RCT (Reactant); SEN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and dehydrohalogenation of)


RN 135616-42-1 CAPLUS

CN 2(1H)-Pyridinone,

3-chloro-3,4-dihydro-1-(4-methoxyphenyl)-3,5-dimethyl-4-phenyl-, cis- (9CI) (CA INDEX NAME)



Relative stereochemistry.

L3 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 135616-43-2 CAPLUS
CN 2(1H)-Pyridinone, 3-bromo-3,4-dihydro-1-(4-methoxyphenyl)-3,5-dimethyl-4-phenyl-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




L3 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

1984:510786 CAPLUS 101:110786

Mesionic oxazolones in heterocyclic synthesis: reaction of 1-aza-3-bromo-1,3-butadienes with 2-phenyl-4-methyl-4 α -oxazolin-5-one

Konwar, Dilip; Sandhu, Jagir; Baruah, J. N.
Reg. Res. Lab., Jorhat, 785 006, India
Indian Journal of Chemistry, Section B: Organic
Chemistry Including Medicinal Chemistry (1993),
22B(12), 1248-9

CODEN: IJSBDB; ISSN: 0376-4699
Journal English
OTHER SOURCE(S): CASREACT 101:110786
GI



AB Phenylmethyloxazolinone I reacts with PhCH:CB₂CH:NC₆H₄R (R = 4-MeO, 4-Cl, 4-Me, 3-NO₂, 4-Br) to give α -pyridones II in good yields, without the formation of any β -lactams.

IT 91506-98-8P 91506-99-9P 91507-00-5P

91507-01-6P 91507-02-7P

RL: SPM (Synthetic preparation); PREP (Preparation)


(preparation of)

RN 91506-99-8 CAPLUS


CN Benzamide, N-[5-bromo-1,2,3,4-tetrahydro-1-(4-methoxyphenyl)-3-oxo-2-

-oxo-4-phenyl-3-pyridinyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 91506-99-9 CAPLUS
CN Benzamide,
N-[5-bromo-1-(4-chlorophenyl)-1,2,3,4-tetrahydro-3-methyl-2-oxo-4-phenyl-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 91507-00-5 CAPLUS
CN Benzamide,
N-[5-bromo-1,2,3,4-tetrahydro-3-methyl-1-(4-methylphenyl)-2-oxo-4-phenyl-3-pyridinyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 91507-01-6 CAPLUS
CN Benzamide,
N-(5-bromo-1,2,3,4-tetrahydro-3-methyl-1-(3-nitrophenyl)-2-oxo-4-phenyl-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 91507-02-7 CAPLUS
CN Benzamide,
N-(5-bromo-1-(4-bromophenyl)-1,2,3,4-tetrahydro-3-methyl-2-oxo-4-phenyl-3-pyridinyl]- (9CI) (CA INDEX NAME)



L3 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

1.3 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1993:453558 CAPLUS
 DOCUMENT NUMBER: 99:53558
 TITLE: Halogenated ketenes. 38. Cycloaddition of α,β -unsaturated imines with ketenes to yield both β - and δ -lactams
 AUTHOR(S): Brady, William T.; Shieh, C. H.
 CORPORATE SOURCE: Dep. Chem., North Texas State Univ., Denton, TX, 76203, USA
 SOURCE: Journal of Organic Chemistry (1983), 48(15), 2499-502
 DOCUMENT TYPE: CASREACT 99:53558
 LANGUAGE: English
 OTHER SOURCE(S): Journal
 AB The cycloaddn. of various types of α,β -unstqd. imines with Ph₂C:CO and Cl₂C:CO yields both (2 + 2) and (4 + 2) cycloaddn. products, i.e., β -lactams and δ -lactams, resp. The cycloaddn. products are dependent upon substitution in the imine and the ketene. The δ -lactams derived from Cl₂C:CO are easily dehydrochlorinated to the corresponding 2-pyridones. All of the results are consistent with a two-step cycloaddn. process involving a dipolar intermediate.
 IT 86129-96-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and dehydrochlorination of)
 RN 86129-96-6 CAPLUS
 CN 2(1H)-Pyridinone, 3,3-dichloro-3,4-dihydro-5-methyl-1,4-diphenyl- (9CI) (CA INDEX NAME)



IT 86129-97-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 86129-97-7 CAPLUS
 CN 2(1H)-Pyridinone, 3-chloro-3,4-dihydro-5-methyl-1,4-diphenyl- (9CI) (CA INDEX NAME)

L3 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

